No One Really Plans to Have MS: Transition Readiness and Quality of Life in Pediatric Multiple Sclerosis
Background: Pediatric MS, defined as onset before the age of 18, is estimated to occur in over 8,000 children in the United States with...
Beyond the Physical Symptoms of Spasticity for Persons with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey
Background: Spasticity, a complex and multi-dimensional symptom of multiple sclerosis (MS), occurs in up to 80% of those with MS. It is...
Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design
Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...
Optical Coherence Tomography As a Biomarker for Multiple Sclerosis Studies
Background: Optic Neuritis occurs in about 20% of MS patients as the initial symptom. Objectives: To assess the clinical utility of optical...